|
Quotes & Info
|
| NLNK > SEC Filings for NLNK > Form 8-K on 19-Jun-2012 | All Recent SEC Filings |
19-Jun-2012
Other Events
On June 19, 2012, NewLink Genetics Corporation (Nasdaq:NLNK) today announced that in the second quarter of 2012 it passed the midpoint in enrollment in its Phase 3 HyperAcute Pancreas immunotherapy product candidate (algenpantucel-L) trial as number of participating institutions reached to 74 sites around the US.
The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
|
|